Published Date: 02 Mar 2023
High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.
Read Full NewsNeurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.
Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.
ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.
Phase 3 DAWN data show daratumumab cuts NMOSD relapse risk 76%, stays well tolerated, and may improve disability, signaling a new targeted option.
Siegel addressed additional points presented in his Maui Derm 2026 session, 'How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10.'
7 Pulmonology Headlines You Missed in January 2026
1.
As EGFR internalization is decreased, BUB1 controls EGFR signaling.
2.
Survey shows cancer anxiety has impact well beyond the individual diagnosed
3.
Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.
4.
Key mechanism behind prostate cancer drug resistance reveals potential new treatment strategy
5.
Cancer patients rarely use ancestry testing.
1.
The benefits and risks of taking fludrocortisone for adrenal insufficiency
2.
7 Subtle Signs of Leukemia: How to Spot the Symptoms Early
3.
The Checkpoint Architect: Unraveling the Mechanisms of PD-L1 Regulation for the Next Generation of Small-Molecule Therapies
4.
Personalized Cancer Vaccines and Neoantigen mRNA: A New Era in Oncology
5.
The Benefits and Risks of Thrombolytics: A Comprehensive Guide
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
2.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III
4.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
5.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation